Sujit S. Nair, PhD, Assistant Professor and Director of GU Immunotherapy Research at the Department of Urology at the Icahn School of Medicine at Mount Sinai
For years, Mount Sinai urologists have been administering radiation and hormone-based therapies to treat patients who present with aggressive prostate cancer. But the battle is about to get more personal with a new clinical trial that is exploring the potential of a personalized vaccine approach.
The phase 1, open-label, single-center, proof-of-concept study is assessing the safety and tolerability of administering a PGV001-based multi-peptide vaccine—a fully personalized therapeutic vaccine directed toward mutation-derived tumor antigens—in combination with CDX-301, a potent hematopoietic cytokine.
Referring a patient is easy. Just click the “Refer a Patient Online” button.
